Immunotherapeutic approaches to cancer treatment use a patient's own immune system to target cancer cells. The side effects associated with traditional treatment options such as chemotherapy and radiation make immunotherapeutic options appealing. The immune system can identify cancer cells in one of two ways: by recognizing tumor-specific antigens or mutations or by recognizing tumor associated antigens. Immunotherapy offers effective treatment options for cancer that offer long-lasting effects with improved overall survival and treatment tolerance. Immunotherapy can also cause organ specific toxicities or immune related adverse events. The recognition of these toxicities and their management is forefront for the clinicians caring for the oncology patient. The Duke Cancer Institute Center for Immunotherapy and the Duke Cancer Network are partnering to utilize a multidisciplinary team of oncology and immunology experts and researchers to educate on immunotoxicities occurring in cancer patients as well as management for these toxicities.